Skeletal  ||| S:0 E:9 ||| JJ
muscle  ||| S:9 E:16 ||| NN
dysfunction  ||| S:16 E:28 ||| NN
in  ||| S:28 E:31 ||| IN
critical  ||| S:31 E:40 ||| JJ
care ||| S:40 E:44 ||| NN
:  ||| S:44 E:46 ||| :
wasting ||| S:46 E:53 ||| CD
,  ||| S:53 E:55 ||| ,
weakness ||| S:55 E:63 ||| NN
,  ||| S:63 E:65 ||| ,
and  ||| S:65 E:69 ||| CC
rehabilitation  ||| S:69 E:84 ||| JJ
strategies  ||| S:84 E:95 ||| NNS
Understanding  ||| S:95 E:109 ||| VBG
the  ||| S:109 E:113 ||| DT
trajectory  ||| S:113 E:124 ||| NN
of  ||| S:124 E:127 ||| IN
skeletal  ||| S:127 E:136 ||| JJ
muscle  ||| S:136 E:143 ||| NN
loss ||| S:143 E:147 ||| NN
,  ||| S:147 E:149 ||| ,
evaluating  ||| S:149 E:160 ||| VBG
its  ||| S:160 E:164 ||| PRP$
relationship  ||| S:164 E:177 ||| NN
to  ||| S:177 E:180 ||| TO
the  ||| S:180 E:184 ||| DT
subsequent  ||| S:184 E:195 ||| JJ
functional  ||| S:195 E:206 ||| JJ
impairment ||| S:206 E:216 ||| NN
,  ||| S:216 E:218 ||| ,
and  ||| S:218 E:222 ||| CC
understanding  ||| S:222 E:236 ||| VBG
the  ||| S:236 E:240 ||| DT
underlying  ||| S:240 E:251 ||| JJ
mechanisms  ||| S:251 E:262 ||| NNS
of  ||| S:262 E:265 ||| IN
skeletal  ||| S:265 E:274 ||| JJ
muscle  ||| S:274 E:281 ||| NN
wasting  ||| S:281 E:289 ||| NN
will  ||| S:289 E:294 ||| MD
provide  ||| S:294 E:302 ||| VB
goals  ||| S:302 E:308 ||| NNS
for  ||| S:308 E:312 ||| IN
novel  ||| S:312 E:318 ||| NN
treatment  ||| S:318 E:328 ||| NN
strategies  ||| S:328 E:339 ||| NNS
in  ||| S:339 E:342 ||| IN
the  ||| S:342 E:346 ||| DT
intensive  ||| S:346 E:356 ||| JJ
care  ||| S:356 E:361 ||| NN
setting ||| S:361 E:368 ||| NN
.  ||| S:368 E:370 ||| .
A  ||| S:370 E:372 ||| DT
focused  ||| S:372 E:380 ||| JJ
approach  ||| S:380 E:389 ||| NN
on  ||| S:389 E:392 ||| IN
the  ||| S:392 E:396 ||| DT
effect  ||| S:396 E:403 ||| NN
of  ||| S:403 E:406 ||| IN
critical  ||| S:406 E:415 ||| JJ
illness  ||| S:415 E:423 ||| NN
on  ||| S:423 E:426 ||| IN
muscle  ||| S:426 E:433 ||| NN
morphology ||| S:433 E:443 ||| NN
,  ||| S:443 E:445 ||| ,
muscle  ||| S:445 E:452 ||| NN
protein  ||| S:452 E:460 ||| NN
turnover ||| S:460 E:468 ||| NN
,  ||| S:468 E:470 ||| ,
and  ||| S:470 E:474 ||| CC
the  ||| S:474 E:478 ||| DT
associated  ||| S:478 E:489 ||| JJ
muscle-signaling  ||| S:489 E:506 ||| JJ
pathways  ||| S:506 E:515 ||| NN
during  ||| S:515 E:522 ||| IN
the  ||| S:522 E:526 ||| DT
early  ||| S:526 E:532 ||| JJ
and  ||| S:532 E:536 ||| CC
recovery  ||| S:536 E:545 ||| NN
stages  ||| S:545 E:552 ||| NNS
of  ||| S:552 E:555 ||| IN
critical  ||| S:555 E:564 ||| JJ
illness  ||| S:564 E:572 ||| NN
is  ||| S:572 E:575 ||| VBZ
required ||| S:575 E:583 ||| VBN
.  ||| S:583 E:585 ||| .
This  ||| S:585 E:590 ||| DT
could  ||| S:590 E:596 ||| MD
potentially  ||| S:596 E:608 ||| RB
lead  ||| S:608 E:613 ||| VB
to  ||| S:613 E:616 ||| TO
targeted  ||| S:616 E:625 ||| JJ
pharmacologic  ||| S:625 E:639 ||| NN
and  ||| S:639 E:643 ||| CC
nonpharmacologic  ||| S:643 E:660 ||| JJ
strategies  ||| S:660 E:671 ||| NNS
to  ||| S:671 E:674 ||| TO
treat ||| S:674 E:679 ||| VB
,  ||| S:679 E:681 ||| ,
or  ||| S:681 E:684 ||| CC
even  ||| S:684 E:689 ||| RB
prevent ||| S:689 E:696 ||| VB
,  ||| S:696 E:698 ||| ,
peripheral  ||| S:698 E:709 ||| JJ
muscle  ||| S:709 E:716 ||| NN
wasting  ||| S:716 E:724 ||| NN
and  ||| S:724 E:728 ||| CC
weakness ||| S:728 E:736 ||| NN
.  ||| S:736 E:738 ||| .
